Filing Details
- Accession Number:
- 0001610717-24-000506
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-10-15 17:29:39
- Reporting Period:
- 2024-10-11
- Accepted Time:
- 2024-10-15 17:29:39
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1628171 | Revolution Medicines Inc. | RVMD | Biological Products, (No Disgnostic Substances) (2836) | 472029180 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1969082 | Jeff Cislini | C/O Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063 | General Counsel | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-10-11 | 6,000 | $36.57 | 51,634 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-10-11 | 6,000 | $50.17 | 45,634 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2024-10-11 | 6,000 | $0.00 | 6,000 | $36.57 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
36,000 | 2024-06-15 | 2030-06-16 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 20, 2024.
- This transaction was executed in multiple trades in prices ranging from $50.00 to $50.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- Includes 40,209 restricted stock units.